BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-2524 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-2524\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07478302-11098@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-2524: Phase 1 readout est. (NCT07478302)
DESCRIPTION:SHR-2524\, phase 1\, Hepatocellular Carcinoma.\nStudy: A Study 
 of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepat
 ocellular Carcinoma\nEstimated primary completion: October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/shr-2524#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07478302
URL:https://assetmemo.bio/drug/shr-2524#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
